<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39353689</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Association of early statin initiation during COVID-19 admission with inpatient mortality at an academic health system in Illinois, March 2020 to September 2022: a target trial emulation using observational data.</ArticleTitle><Pagination><StartPage>e085547</StartPage><MedlinePgn>e085547</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e085547</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2024-085547</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We assessed the association of early statin initiation with inpatient mortality among hospitalised COVID-19 patients.</AbstractText><AbstractText Label="DESIGN, SETTING AND PARTICIPANTS" NlmCategory="METHODS">This observational study emulated a hypothetical target trial using electronic health records data from Northwestern Medicine Health System, Illinois, 2020-2022. We included patients who were ≥40 years, admitted ≥48 hours for COVID-19 from March 2020 to August 2022 and had no evidence of statin use before admission.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Individuals who initiated any statins within 48 hours of admission were compared with individuals who did not initiate statins during this period.</AbstractText><AbstractText Label="PRIMARY OUTCOME MEASURES" NlmCategory="METHODS">Inpatient mortality at hospital days 7, 14, 21 and 28 were determined using hospital records. Risk differences between exposure groups were calculated using augmented inverse propensity weighting (AIPW) with SuperLearner.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 8893 individuals (24.5% early statin initiators) were included. Early initiators tended to be older, male and have higher comorbidity burdens. Unadjusted day 28 mortality was higher in early initiators (6.0% vs 3.6%). Adjusted analysis showed slightly higher inpatient mortality risk at days 7 (RD: 0.5%, 95% CI: 0.2 to 0.8) and 21 (RD: 0.6%, 95% CI: 0.04 to 1.1), but not days 14 (RD: 0.4%, 95% CI: -0.03 to 0.9) and 28 (RD: 0.4%, 95% CI: -0.2 to 1.1). Sensitivity analyses using alternative modelling approaches showed no difference between groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Early statin initiation was not associated with lower mortality contrasting with findings of previous observational studies. Trial emulation helped in identifying and addressing sources of bias incompletely addressed by previous work. Statin use may be indicated for other conditions but not COVID-19.</AbstractText><CopyrightInformation>© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rivera</LastName><ForeName>Adovich</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2533-0818</Identifier><AffiliationInfo><Affiliation>Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Heeti</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Southern Illinois University System, Carbondale, Illinois, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feinstein</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Janna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taiwo</LastName><ForeName>Babafemi</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Havey Institute for Global Health, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Achenbach</LastName><ForeName>Chad</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Havey Institute for Global Health, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petito</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, Division of Biostatistics and Informatics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA lucia.petito@northwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001422</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="Y">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007087" MajorTopicYN="N" Type="Geographic">Illinois</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="Y">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">epidemiologic studies</Keyword><Keyword MajorTopicYN="N">inpatients</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">statistics &amp; research methods</Keyword></KeywordList><CoiStatement>Competing interests: LP receives funds for unrelated research from Omron Healthcare Co. Other authors have no other conflicts to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>3</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>3</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>20</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39353689</ArticleId><ArticleId IdType="pmc">PMC11448146</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2024-085547</ArticleId><ArticleId IdType="pii">bmjopen-2024-085547</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang H, Paulson KR, Pease SA. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet. 2022;399:1513–36. doi: 10.1016/S0140-6736(21)02796-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02796-3</ArticleId><ArticleId IdType="pmc">PMC8912932</ArticleId><ArticleId IdType="pubmed">35279232</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi RT, Malani PN, del Rio C. COVID-19 Therapeutics for Nonhospitalized Patients. JAMA. 2022;327:617. doi: 10.1001/jama.2022.0335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.0335</ArticleId><ArticleId IdType="pubmed">35029659</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami N, Hayden R, Hills T, et al. Therapeutic advances in COVID-19. Nat Rev Nephrol. 2023;19:38–52. doi: 10.1038/s41581-022-00642-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-022-00642-4</ArticleId><ArticleId IdType="pmc">PMC9574806</ArticleId><ArticleId IdType="pubmed">36253508</ArticleId></ArticleIdList></Reference><Reference><Citation>Li GM, Li YG, Yamate M, et al. Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle. Microbes Infect. 2007;9:96–102. doi: 10.1016/j.micinf.2006.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2006.10.015</ArticleId><ArticleId IdType="pmc">PMC7110773</ArticleId><ArticleId IdType="pubmed">17194611</ArticleId></ArticleIdList></Reference><Reference><Citation>Radenkovic D, Chawla S, Pirro M, et al. Cholesterol in Relation to COVID-19: Should We Care about It? J Clin Med . 2020;9:1909. doi: 10.3390/jcm9061909.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9061909</ArticleId><ArticleId IdType="pmc">PMC7356583</ArticleId><ArticleId IdType="pubmed">32570882</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Madhavan MV, Poterucha TJ, et al. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Nat Commun. 2021;12:1325. doi: 10.1038/s41467-021-21553-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21553-1</ArticleId><ArticleId IdType="pmc">PMC7910606</ArticleId><ArticleId IdType="pubmed">33637713</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal N, Cao Z, Gundrum J, et al. Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19. JAMA Netw Open . 2020;3:e2029058. doi: 10.1001/jamanetworkopen.2020.29058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.29058</ArticleId><ArticleId IdType="pmc">PMC7729428</ArticleId><ArticleId IdType="pubmed">33301018</ArticleId></ArticleIdList></Reference><Reference><Citation>Permana H, Huang I, Purwiga A, et al. In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis. Pharmacol Rep. 2021;73:769–80. doi: 10.1007/s43440-021-00233-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-021-00233-3</ArticleId><ArticleId IdType="pmc">PMC7895740</ArticleId><ArticleId IdType="pubmed">33608850</ArticleId></ArticleIdList></Reference><Reference><Citation>Zein A, Sulistiyana CS, Khasanah U, et al. Statin and mortality in COVID-19: a systematic review and meta-analysis of pooled adjusted effect estimates from propensity-matched cohorts. Postgrad Med J. 2022;98:503–8. doi: 10.1136/postgradmedj-2021-140409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2021-140409</ArticleId><ArticleId IdType="pubmed">34193549</ArticleId></ArticleIdList></Reference><Reference><Citation>Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial. BMJ. 2022:e068407. doi: 10.1136/bmj-2021-068407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068407</ArticleId><ArticleId IdType="pubmed">34996756</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazloomzadeh S, Khaleghparast S, Ghadrdoost B, et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. JAMA . 2021;325:1620. doi: 10.1001/jama.2021.4152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.4152</ArticleId><ArticleId IdType="pmc">PMC7974835</ArticleId><ArticleId IdType="pubmed">33734299</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghati N, Bhatnagar S, Mahendran M, et al. Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: a randomised clinical trial (RESIST trial) BMC Infect Dis. 2022;22:606. doi: 10.1186/s12879-022-07570-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07570-5</ArticleId><ArticleId IdType="pmc">PMC9270743</ArticleId><ArticleId IdType="pubmed">35810307</ArticleId></ArticleIdList></Reference><Reference><Citation>Xavier DP, Lima GC, Gomes LGF, et al. Effects of statin therapy in hospitalized adult COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. Einstein (São Paulo) 2023;21:eRW0351. doi: 10.31744/einstein_journal/2023RW0351.</Citation><ArticleIdList><ArticleId IdType="doi">10.31744/einstein_journal/2023RW0351</ArticleId><ArticleId IdType="pmc">PMC10247280</ArticleId><ArticleId IdType="pubmed">37341222</ArticleId></ArticleIdList></Reference><Reference><Citation>Davoodi L, Jafarpour H, Oladi Z, et al. Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial. Int J Cardiol Heart Vasc. 2021;36:100875. doi: 10.1016/j.ijcha.2021.100875.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcha.2021.100875</ArticleId><ArticleId IdType="pmc">PMC8437805</ArticleId><ArticleId IdType="pubmed">34541293</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghafoori M, Saadati H, Taghavi M, et al. Survival of the hospitalized patients with COVID‐19 receiving atorvastatin: A randomized clinical trial. J Med Virol. 2022;94:3160–8. doi: 10.1002/jmv.27710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27710</ArticleId><ArticleId IdType="pmc">PMC9088596</ArticleId><ArticleId IdType="pubmed">35274326</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA. 2006;295:74–80. doi: 10.1001/jama.295.1.74.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.295.1.74</ArticleId><ArticleId IdType="pubmed">16391219</ArticleId></ArticleIdList></Reference><Reference><Citation>Emilsson L, García-Albéniz X, Logan RW, et al. Examining Bias in Studies of Statin Treatment and Survival in Patients With Cancer. JAMA Oncol. 2018;4:63–70. doi: 10.1001/jamaoncol.2017.2752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2017.2752</ArticleId><ArticleId IdType="pmc">PMC5790310</ArticleId><ArticleId IdType="pubmed">28822996</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernán MA, Wang W, Leaf DE. Target Trial Emulation: A Framework for Causal Inference From Observational Data. JAMA. 2022;328:2446–7. doi: 10.1001/jama.2022.21383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.21383</ArticleId><ArticleId IdType="pubmed">36508210</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernán MA, Sauer BC, Hernández-Díaz S, et al. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70–5. doi: 10.1016/j.jclinepi.2016.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2016.04.014</ArticleId><ArticleId IdType="pmc">PMC5124536</ArticleId><ArticleId IdType="pubmed">27237061</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahan BC, Jairath V, Doré CJ, et al. The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies. Trials. 2014;15:139. doi: 10.1186/1745-6215-15-139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1745-6215-15-139</ArticleId><ArticleId IdType="pmc">PMC4022337</ArticleId><ArticleId IdType="pubmed">24755011</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuler MS, Rose S. Targeted Maximum Likelihood Estimation for Causal Inference in Observational Studies. Am J Epidemiol. 2017;185:65–73. doi: 10.1093/aje/kww165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kww165</ArticleId><ArticleId IdType="pubmed">27941068</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Y, Brooks MM, Kennedy EH, et al. Use of Machine Learning to Estimate the Per-Protocol Effect of Low-Dose Aspirin on Pregnancy Outcomes: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open . 2022;5:e2143414. doi: 10.1001/jamanetworkopen.2021.43414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.43414</ArticleId><ArticleId IdType="pmc">PMC8908068</ArticleId><ArticleId IdType="pubmed">35262718</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirracchio R, Petersen ML, van der Laan M. Improving propensity score estimators’ robustness to model misspecification using super learner. Am J Epidemiol. 2015;181:108–19. doi: 10.1093/aje/kwu253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwu253</ArticleId><ArticleId IdType="pmc">PMC4351345</ArticleId><ArticleId IdType="pubmed">25515168</ArticleId></ArticleIdList></Reference><Reference><Citation>Young JG, Stensrud MJ, Tchetgen Tchetgen EJ, et al. A causal framework for classical statistical estimands in failure-time settings with competing events. Stat Med. 2020;39:1199–236. doi: 10.1002/sim.8471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.8471</ArticleId><ArticleId IdType="pmc">PMC7811594</ArticleId><ArticleId IdType="pubmed">31985089</ArticleId></ArticleIdList></Reference><Reference><Citation>Benkeser D, Hejazi N. survtmle: Targeted minimum loss-based estimation for survival analysis. 2020. https://github.com/benkeser/survtmle Available.</Citation></Reference><Reference><Citation>Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010;33:1–22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929880</ArticleId><ArticleId IdType="pubmed">20808728</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright MN, Ziegler A. ranger: A Fast Implementation of Random Forests for High Dimensional Data in C++ and R. J Stat Soft. 77 doi: 10.18637/jss.v077.i01. n.d.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v077.i01</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Guestrin C.  New York, NY, US: Association for Computing Machinery; XGBoost: a scalable tree boosting system. in: proceedings of the 22nd acm sigkdd international conference on knowledge discovery and data mining.http://doi.acm.org/10.1145/2939672.2939785 Available.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2939672.2939785</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray EJ, Caniglia EC, Petito LC. Causal survival analysis: A guide to estimating intention-to-treat and per-protocol effects from randomized clinical trials with non-adherence. Res Methods Med Health Sci. 2021;2:39–49. doi: 10.1177/2632084320961043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2632084320961043</ArticleId></ArticleIdList></Reference><Reference><Citation>Cariou B, Goronflot T, Rimbert A, et al. Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: Results from the CORONADO study. Diabetes Metab. 2021;47:101202. doi: 10.1016/j.diabet.2020.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabet.2020.10.001</ArticleId><ArticleId IdType="pmc">PMC7572108</ArticleId><ArticleId IdType="pubmed">33091555</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohia P, Kapur S, Benjaram S, et al. Statins and clinical outcomes in hospitalized COVID-19 patients with and without Diabetes Mellitus: a retrospective cohort study with propensity score matching. Cardiovasc Diabetol. 2021;20:140. doi: 10.1186/s12933-021-01336-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01336-0</ArticleId><ArticleId IdType="pmc">PMC8272452</ArticleId><ArticleId IdType="pubmed">34246277</ArticleId></ArticleIdList></Reference><Reference><Citation>Stekhoven DJ, Bühlmann P. MissForest--non-parametric missing value imputation for mixed-type data. Bioinformatics. 2012;28:112–8. doi: 10.1093/bioinformatics/btr597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btr597</ArticleId><ArticleId IdType="pubmed">22039212</ArticleId></ArticleIdList></Reference><Reference><Citation>Lao US, Law CF, Baptista-Hon DT, et al. Systematic Review and Meta-Analysis of Statin Use and Mortality, Intensive Care Unit Admission and Requirement for Mechanical Ventilation in COVID-19 Patients. J Clin Med . 2022;11:5454. doi: 10.3390/jcm11185454.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11185454</ArticleId><ArticleId IdType="pmc">PMC9501062</ArticleId><ArticleId IdType="pubmed">36143101</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88. doi: 10.1016/0197-2456(86)90046-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. J Stat Soft. 2010;36 doi: 10.18637/jss.v036.i03.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v036.i03</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouhpeikar H, Khosaravizade Tabasi H, Khazir Z, et al. Statin Use in COVID-19 Hospitalized Patients and Outcomes: A Retrospective Study. Front Cardiovasc Med. 2022;9:820260. doi: 10.3389/fcvm.2022.820260.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.820260</ArticleId><ArticleId IdType="pmc">PMC8907562</ArticleId><ArticleId IdType="pubmed">35282379</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Nava G, Trelles-Garcia DP, Yanez-Bello MA, et al. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study. Crit Care. 2020;24:429. doi: 10.1186/s13054-020-03154-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03154-4</ArticleId><ArticleId IdType="pmc">PMC7358561</ArticleId><ArticleId IdType="pubmed">32664990</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera AS, Al-Heeti O, Petito LC, et al. Association of statin use with outcomes of patients admitted with COVID-19: an analysis of electronic health records using superlearner. BMC Infect Dis. 2023;23:115. doi: 10.1186/s12879-023-08026-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08026-0</ArticleId><ArticleId IdType="pmc">PMC9951166</ArticleId><ArticleId IdType="pubmed">36829115</ArticleId></ArticleIdList></Reference><Reference><Citation>Memel ZN, Lee JJ, Foulkes AS, et al. Association of Statins and 28-Day Mortality Rates in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Infect Dis. 2022;225:19–29. doi: 10.1093/infdis/jiab539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab539</ArticleId><ArticleId IdType="pmc">PMC8586726</ArticleId><ArticleId IdType="pubmed">34665852</ArticleId></ArticleIdList></Reference><Reference><Citation>Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet. 1997;32:403–25. doi: 10.2165/00003088-199732050-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-199732050-00005</ArticleId><ArticleId IdType="pubmed">9160173</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow R, Im J, Chiu N, et al. The protective association between statins use and adverse outcomes among COVID-19 patients: A systematic review and meta-analysis. PLoS One. 2021;16:e0253576. doi: 10.1371/journal.pone.0253576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0253576</ArticleId><ArticleId IdType="pmc">PMC8224908</ArticleId><ArticleId IdType="pubmed">34166458</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollias A, Kyriakoulis KG, Kyriakoulis IG, et al. Statin use and mortality in COVID-19 patients: Updated systematic review and meta-analysis. Atherosclerosis. 2021;330:114–21. doi: 10.1016/j.atherosclerosis.2021.06.911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2021.06.911</ArticleId><ArticleId IdType="pmc">PMC8233054</ArticleId><ArticleId IdType="pubmed">34243953</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu KS, Lin PC, Chen YS, et al. The use of statins was associated with reduced COVID-19 mortality: a systematic review and meta-analysis. Ann Med. 2021;53:874–84. doi: 10.1080/07853890.2021.1933165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2021.1933165</ArticleId><ArticleId IdType="pmc">PMC8189130</ArticleId><ArticleId IdType="pubmed">34096808</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Arocutipa C, Melgar-Talavera B, Alvarado-Yarasca Á, et al. Statins reduce mortality in patients with COVID-19: an updated meta-analysis of 147 824 patients. Int J Infect Dis. 2021;110:374–81. doi: 10.1016/j.ijid.2021.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.08.004</ArticleId><ArticleId IdType="pmc">PMC8349445</ArticleId><ArticleId IdType="pubmed">34375760</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman KL, Schenck EJ, Satlin MJ, et al. Comparison of a Target Trial Emulation Framework vs Cox Regression to Estimate the Association of Corticosteroids With COVID-19 Mortality. JAMA Netw Open . 2022;5:e2234425. doi: 10.1001/jamanetworkopen.2022.34425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.34425</ArticleId><ArticleId IdType="pmc">PMC9530966</ArticleId><ArticleId IdType="pubmed">36190729</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas M, Rahaman S, Biswas TK, et al. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Intervirology. 2021;64:36–47. doi: 10.1159/000512592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000512592</ArticleId><ArticleId IdType="pmc">PMC7801974</ArticleId><ArticleId IdType="pubmed">33296901</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur B, Dubey P, Benitez J, et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. Sci Rep. 2021;11:8562. doi: 10.1038/s41598-021-88130-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-88130-w</ArticleId><ArticleId IdType="pmc">PMC8058064</ArticleId><ArticleId IdType="pubmed">33879826</ArticleId></ArticleIdList></Reference><Reference><Citation>VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med. 2017;167:268–74. doi: 10.7326/M16-2607.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M16-2607</ArticleId><ArticleId IdType="pubmed">28693043</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatton A, Le Borgne F, Leyrat C, et al. G-computation, propensity score-based methods, and targeted maximum likelihood estimator for causal inference with different covariates sets: a comparative simulation study. Sci Rep. 2020;10:9219. doi: 10.1038/s41598-020-65917-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-65917-x</ArticleId><ArticleId IdType="pmc">PMC7280276</ArticleId><ArticleId IdType="pubmed">32514028</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurz CF. Augmented Inverse Probability Weighting and the Double Robustness Property. Med Decis Making. 2022;42:156–67. doi: 10.1177/0272989X211027181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0272989X211027181</ArticleId><ArticleId IdType="pmc">PMC8793316</ArticleId><ArticleId IdType="pubmed">34225519</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2020:ciaa478. doi: 10.1093/cid/ciaa478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa478</ArticleId><ArticleId IdType="pmc">PMC7197612</ArticleId><ArticleId IdType="pubmed">32338708</ArticleId></ArticleIdList></Reference><Reference><Citation>Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. 2016;316:1997. doi: 10.1001/jama.2016.15450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.15450</ArticleId><ArticleId IdType="pubmed">27838723</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>